ReviewFrontiers in molecular biosciences2026
Glycoengineering strategies for constructing defined Mucin O-glycans.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucins are densely O-glycosylated proteins that establish mucosal barriers, mediate immune recognition, and serve as ligands for host lectins and microbes. However, mucin O-glycan structure-function relationships remain poorly defined due to inherent glycoform heterogeneity. Glycoengineering has emerged as a suite of methodologies enabling construction of mucins and mucin-type glycoconjugates with defined O-glycan structures suitable for rigorous biochemical and biophysical investigation. Here, we evaluate three glycoengineering approaches from a practical methodology perspective, emphasizing analytical validation requirements and method selection criteria. Cellular glycoengineering exploits genetic reconstruction of glycosylation pathways to produce simplified glycoforms in living cells, offering scalability and native protein context but limited homogeneity. Chemoenzymatic synthesis employs purified or cell-free-derived glycosyltransferases for sequential
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.